Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Syndax Pharmaceuticals is a biopharmaceutical company focused on developing innovative cancer therapies. Its core products include FDA-approved revumenib for acute leukemia and axatilimab for chronic graft-versus-host disease, with ongoing clinical programs in oncology and fibrotic diseases. The company leverages licensing, collaborations, and a strong pipeline to address unmet medical needs in hematology, oncology, and fibrosis markets worldwide.
This description was generated via AI from an annual report. Updated about 1 year ago.